GSK has for some time been a major client for Genevac's centrifugal evaporation systems and this agreement builds on that relationship to make it easier for scientists to acquire this technology
Supplier of solvent removal systems for drug discovery, Genevac, has reached an agreement with GlaxoSmithKline under which Genevac will become a preferred supplier of such technology to all GSK sites in Europe.
GSK has for some time been a major client for Genevac's advanced centrifugal evaporation systems and this agreement builds on that relationship to make it easier for GSK scientists to acquire this technology.
Preferential terms and special training packages make it economically viable for GSK while ensuring that each laboratory has a competent trained 'super user' for their Genevac systems.
Commenting on this agreement, Genevac's key account manager for GSK, Rob Darrington, commented: "We have been talking about this for some time with various GSK sites.
"I am pleased that with final legal clearence, this agreement can now come into force. "GSK researchers will see immediate benefits as specialist training is delivered, and re-ordering of consumables, spares and additional capacity becomes routine under the agreement".
A Genevac spokesperson said that further preferred supplier agreements of this type would be forthcoming with their major clients: "We are in the long-term business of developing systems which our key accounts need to enhance their research, either through additional capacity or better performance with difficult samples.
"We have always worked closely with big pharma and preferred supplier agreements are a logical extension, formalising our arrangements with each other".
